GSK (LON:GSK) Stock Rating Reaffirmed as “Buy” by Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Financial Group in a research report issued on Tuesday, Digital Look reports. They presently have a GBX 2,500 price target on the stock. Jefferies Financial Group’s price target points to a potential upside of 33.80% from the company’s previous close.

GSK has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Tuesday, September 29th. Berenberg Bank upped their price target on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a report on Tuesday, September 15th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 1,975 price target on shares of GSK in a research report on Tuesday, September 8th. Two equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of GBX 2,064.38.

GSK Stock Performance

GSK stock traded up GBX 13.50 during midday trading on Tuesday, hitting GBX 1,868.50. 5,106,011 shares of the company traded hands, compared to its average volume of 12,483,875. GSK has a twelve month low of GBX 1,592 and a twelve month high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36. The business has a 50 day simple moving average of GBX 1,845.67 and a 200-day simple moving average of GBX 1,924.07. The stock has a market capitalization of £74.87 billion, a price-to-earnings ratio of 15.86, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last released its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, equities research analysts predict that GSK will post 175.98 earnings per share for the current year.

Insider Transactions at GSK

In related news, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction dated Friday, September 18th. The shares were bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal acquired 637 shares of the company’s stock in a transaction on Friday, September 18th. The shares were bought at an average price of GBX 4,985 per share, with a total value of £31,754.45. Insiders have bought 2,151 shares of company stock valued at $6,021,921 in the last ninety days. 0.20% of the stock is owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.